NEW YORK (Reuters Health) – While oxybutynin is often used prophylactically to reduce irritative urinary symptoms related to intravesical bacillus Calmette-Guerin (BCG) therapy for bladder cancer, it actually…
NEW YORK (Reuters Health) – In patients with liver cancer related to hepatitis B virus (HBV) infection, giving nucleoside analogues after curative surgery appears to reduce the risk…
NEW YORK (Reuters Health) – Reduced-intensity conditioning that includes two daily 2.5-mg/kg doses of antithymocyte globulin before allogeneic stem-cell transplantation for hematologic malignancy significantly reduces graft-versus-host disease (GvHD)…
NEW YORK (Reuters Health) – Even the best strategies for selectively testing colorectal CRC tumors for mismatch repair (MMR) gene mutations will miss 5% to 15% of Lynch…
NEW YORK (Reuters Health) – The use of tumor necrosis factor alpha inhibitors (TNF-I) therapy for various immune-mediated chronic inflammatory diseases does not increase the risk of cancer,…
NEW YORK (Reuters Health) – Two independent studies have shown that long-term outcomes are better with radiotherapy and chemotherapy rather than radiotherapy alone in patients with anaplastic oligodendrogliomas…
Oriane Chausiaux, PhD, and Shamus Husheer, PhD, discuss DuoFertility, a new method to aid couples struggling with infertility. The program monitors over 20,000 physiological measurements to guide couples on the best ways to conceive…
NEW YORK (Reuters Health) – A test that measures levels of the protein fibulin-3 in blood and pleural fluid can identify people with pleural mesothelioma and might someday…
NEW YORK (Reuters Health) – A retrospective multicenter study conducted in France concludes that combination chemotherapy with gemcitabine and oxaliplatin is effective in patients with advanced hepatocellular carcinoma…
NEW YORK (Reuters Health) – Compared to open radical prostatectomy in patients with recurrent prostate cancer after failed primary therapy, robotic-assisted laparoscopic prostatectomy “is an attractive alternative”, and…
